Orrin is a neurologist who directs the NYU Langone Epilepsy Center, one of the world’s premier centers.  NYU’s Neurology & Neurosurgery departments were ranked #1 by US News & World Report. He has participated in studies leading to approval of >10 antiseizure medications and neuromodulatory devices and was the Principal investigator for the landmark FDA approval of a cannabis-based medication, cannabidiol.

Orrin has published more than 500 peer reviewed articles and written or edited more than 20 books in neurology, psychiatry, neurosurgery, cognition, and basic science. He has served on the scientific advisory board for more than 12 rare genetic disorder organizations.

He founded several gene therapy/molecular biology startups and continues to serve on the Board of Directors for multiple biotech companies focused on novel therapeutics.